| Literature DB >> 12887902 |
Katrin Kaehlcke1, Alexander Dorr, Claudia Hetzer-Egger, Veronique Kiermer, Peter Henklein, Martina Schnoelzer, Erwann Loret, Philip A Cole, Eric Verdin, Melanie Ott.
Abstract
The HIV transcriptional activator Tat is acetylated by p300 at a single lysine residue in the TAR RNA binding domain. We have generated monoclonal and polyclonal antibodies specific for the acetylated form of Tat (AcTat). Microinjection of anti-AcTat antibodies inhibited Tat-mediated transactivation in cells. Similarly, the p300 inhibitor Lys-CoA and siRNA specific for p300 suppressed Tat transcriptional activity. Full-length synthetic AcTat bound to TAR RNA with the same affinity as unacetylated Tat, but formation of a Tat-TAR-CyclinT1 ternary complex was completely inhibited in the presence of AcTat. We propose that Tat acetylation may help in dissociating the Tat cofactor CyclinT1 from TAR RNA and serve to transfer Tat onto the elongating RNA polymerase II.Entities:
Mesh:
Substances:
Year: 2003 PMID: 12887902 DOI: 10.1016/s1097-2765(03)00245-4
Source DB: PubMed Journal: Mol Cell ISSN: 1097-2765 Impact factor: 17.970